drugset
drugset / Trial / NCT04723810

TumorGlow Intraoperative Molecular Imaging (IMI)

NCT04723810 ↗

Phase 1/2 Recruiting 500 enrolled University of Pennsylvania
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 1/2 study in patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who are considered to be good surgical candidates to evaluate the safety and efficacy of the image-guided surgery using indocyanine green for intramolecular imaging of solid tumors.

Timeline

Start
2024-08-14
Primary completion
2027-01-14
Completion
2027-01-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Indocyanine Green Diagnostic / imaging agent 1 mg/kg Intravenous
Subject Indocyanine Green Diagnostic / imaging agent 5 mg/kg Intravenous

Indications

No indication recorded.